PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21964533-2	2011	We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy.	mpm	115-118	vascular endothelial growth factor A	Homo sapiens	46-50
27032653-6	2016	Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002).	mpm	45-48	epidermal growth factor receptor	Homo sapiens	85-89
27032653-6	2016	Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002).	mpm	45-48	thioredoxin	Homo sapiens	91-94
27032653-6	2016	Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002).	mpm	45-48	mesothelin	Homo sapiens	96-100
27032653-6	2016	Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002).	mpm	45-48	EGF containing fibulin extracellular matrix protein 1	Homo sapiens	106-115
27032653-6	2016	Compared to the asbestos exposure group, the MPM group had significantly higher mean EGFR, TRX, SMRP, and fibulin-3 levels (p = 0.041, p = 0.023, p = 0.002, and p = 0.001, respectively), and significantly lower mean SDC-1 levels (p = 0.002).	mpm	45-48	syndecan 1	Homo sapiens	216-221
26238284-9	2015	Taken together, our results indicate that Nox4-mediated ROS, at least in part, transmit cell survival signals and their depletion leads to apoptosis, thus highlighting the Nox4-ROS-AKT signaling pathway as a potential therapeutic target for MPM treatment.	mpm	241-244	NADPH oxidase 4	Homo sapiens	42-46
26238284-9	2015	Taken together, our results indicate that Nox4-mediated ROS, at least in part, transmit cell survival signals and their depletion leads to apoptosis, thus highlighting the Nox4-ROS-AKT signaling pathway as a potential therapeutic target for MPM treatment.	mpm	241-244	NADPH oxidase 4	Homo sapiens	172-176
26238284-9	2015	Taken together, our results indicate that Nox4-mediated ROS, at least in part, transmit cell survival signals and their depletion leads to apoptosis, thus highlighting the Nox4-ROS-AKT signaling pathway as a potential therapeutic target for MPM treatment.	mpm	241-244	AKT serine/threonine kinase 1	Homo sapiens	181-184
21257028-8	2011	After 12 wk of treatment, the relative TG decrease from baseline reached 9.8%, whereas LDL-C was slightly decreased (by 1.5%) following MPM treatment compared with placebo in the intention-to-treat cohort.	mpm	136-139	component of oligomeric golgi complex 2	Homo sapiens	87-92
21167756-2	2010	Here we present the crystal structure of CD1c at 2.5 A resolution, in complex with the pathogenic Mycobacterium tuberculosis antigen mannosyl-beta1-phosphomycoketide (MPM).	mpm	167-170	CD1c molecule	Homo sapiens	41-45
19184347-6	2009	A considerable reduction in the cytokine and chemokine production, mostly TNFalpha, IL-1beta and IL-6 production in the MPM-treated group, suggested an inhibition of the mediators responsible for leukocyte extravasation.	mpm	120-123	tumor necrosis factor	Mus musculus	74-82
20406141-9	2010	In spontaneously hypertensive rats, MPM-treated animals showed a reduction of SBP by at least 13% (P < .05) for 4 weeks.	mpm	36-39	spermine binding protein	Rattus norvegicus	78-81
19184347-6	2009	A considerable reduction in the cytokine and chemokine production, mostly TNFalpha, IL-1beta and IL-6 production in the MPM-treated group, suggested an inhibition of the mediators responsible for leukocyte extravasation.	mpm	120-123	interleukin 1 beta	Mus musculus	84-92
19184347-6	2009	A considerable reduction in the cytokine and chemokine production, mostly TNFalpha, IL-1beta and IL-6 production in the MPM-treated group, suggested an inhibition of the mediators responsible for leukocyte extravasation.	mpm	120-123	interleukin 6	Mus musculus	97-101
12921972-3	2003	We now report that pre-treatment of MPM with the lipid portion of oxLDL induced a reduction both in the degradation of internalized small macromolecules such as maleylated (mal) BSA (30%) or larger ones such as aggregated LDL (100%), and in cellular cathepsin B activity (42%).	mpm	36-39	cathepsin B	Mus musculus	250-261
6236548-3	1984	Pretreatment of MPM with 10(2)-10(3) U/ml of Mu IFN-alpha/beta for 24 h enhanced both attachment and ingestion of bacteria or erythrocytes mediated by the non-specific receptor, the Fc receptor, or the C3b receptor.	mpm	16-19	Fc receptor	Mus musculus	182-193
8897701-4	1996	When compared to the control group, in MPM group, plasma u-PA and t-PA antigen levels were higher, but plasma u-PA and t-PA activity were comparable.	mpm	39-42	plasminogen activator, urokinase	Homo sapiens	57-61
8897701-4	1996	When compared to the control group, in MPM group, plasma u-PA and t-PA antigen levels were higher, but plasma u-PA and t-PA activity were comparable.	mpm	39-42	plasminogen activator, tissue type	Homo sapiens	66-70
9827714-18	1998	CONCLUSIONS: These results confirm that intrapleural administration of IL-2 is well tolerated and has antitumor activity in patients with MPM.	mpm	138-141	interleukin 2	Homo sapiens	71-75
34988770-8	2022	Decreased collagen percentage and increased OPN immunoreactivity showed significant results in the MPM group as compared with PRF at 4 and 8 weeks postoperatively, respectively.	mpm	99-102	secreted phosphoprotein 1	Canis lupus familiaris	44-47
35212722-7	2022	Upregulation of mucin1 and mucin16 in HCECs promoted by MPM or by diquafosol treatment impeded intracellular fluorescein ingress.	mpm	56-59	mucin 1, cell surface associated	Homo sapiens	16-22
35212722-7	2022	Upregulation of mucin1 and mucin16 in HCECs promoted by MPM or by diquafosol treatment impeded intracellular fluorescein ingress.	mpm	56-59	mucin 16, cell surface associated	Homo sapiens	27-34
6236548-5	1984	In contrast, treatment of MPM with 10(1)-10(2)U/ml of Mu IFN-gamma suppressed attachment and ingestion of non-opsonized and IgG-opsonized E. coli and of E-IgG by 10-40%.	mpm	26-29	interferon gamma	Mus musculus	57-66
32493992-7	2020	Novel LDH-A inhibitors enhanced spheroid disintegration and displayed synergistic effects with pemetrexed in MPM and gemcitabine in DMPM cells.	mpm	109-112	lactate dehydrogenase A	Homo sapiens	6-11
33987368-3	2021	The aim of the present study was to investigate the mechanism of MTA1 and chemo-resistance in MPM.	mpm	94-97	metastasis associated 1	Homo sapiens	65-69
33987368-12	2021	Our findings indicate that MTA1 could serve as a novel therapeutic target to overcome chemoresistance in MPM.	mpm	105-108	metastasis associated 1	Homo sapiens	27-31
32600123-8	2020	Our report describes the detection of EML4-ALK rearrangement in a patient with MPM who had remarkable therapeutic response with ALK inhibitors.	mpm	79-82	EMAP like 4	Homo sapiens	38-42
32600123-8	2020	Our report describes the detection of EML4-ALK rearrangement in a patient with MPM who had remarkable therapeutic response with ALK inhibitors.	mpm	79-82	ALK receptor tyrosine kinase	Homo sapiens	43-46
32600123-8	2020	Our report describes the detection of EML4-ALK rearrangement in a patient with MPM who had remarkable therapeutic response with ALK inhibitors.	mpm	79-82	ALK receptor tyrosine kinase	Homo sapiens	128-131
29419731-9	2018	Moreover, levels of interleukin (IL)-6, one of the most important cytokines in chronic inflammation, in cultured supernatants were higher in PP and MPM patients compared with HD.	mpm	148-151	interleukin 6	Homo sapiens	20-38
32517259-14	2020	Conclusions: Our data show that TGFalpha but not its receptor EGFR is a key factor in resistance to MPM chemotherapy.	mpm	100-103	transforming growth factor alpha	Homo sapiens	32-40
32517259-15	2020	This observation may contribute to casting light on the promising but still controversial role of EGFR signaling in MPM therapy.	mpm	116-119	epidermal growth factor receptor	Homo sapiens	98-102